Plain-English translation of NCT04373564 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is tracking whether gadolinium-based contrast agents — special dyes injected before brain scans to help doctors see images more clearly — might affect how your brain works over time. Researchers will compare people who receive repeated injections of gadolinium with people who don't receive it, measuring memory, thinking ability, and movement over 5 years to make sure the dye is safe.
Gadolinium contrast dye has been used safely in medical imaging for decades, but researchers want to confirm that when patients need multiple scans over many years, the dye doesn't gradually build up in the body or affect brain function.
You likely qualify if…
You likely don't qualify if…
If you join the contrast dye group, you'll continue receiving your regularly scheduled contrast-enhanced MRI scans as part of your medical care — the study doesn't add extra scans for treatment purposes. You'll also complete yearly memory and movement tests, brain imaging at the start and end of the study, and provide blood and urine samples once a year to measure dye levels in your body. The control group (people not receiving contrast dye) will undergo similar testing and imaging, but without the dye injections. The entire study lasts 5 years.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States